Segall Bryant & Hamill LLC increased its holdings in Array Biopharma Inc (NASDAQ:ARRY) by 26.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 46,504 shares of the biopharmaceutical company’s stock after acquiring an additional 9,852 shares during the period. Segall Bryant & Hamill LLC’s holdings in Array Biopharma were worth $663,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Meeder Asset Management Inc. raised its stake in shares of Array Biopharma by 635.8% in the fourth quarter. Meeder Asset Management Inc. now owns 2,097 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 1,812 shares in the last quarter. Exane Derivatives acquired a new stake in shares of Array Biopharma in the fourth quarter valued at $39,000. IFP Advisors Inc acquired a new stake in shares of Array Biopharma in the fourth quarter valued at $40,000. Bank of Montreal Can raised its stake in shares of Array Biopharma by 47.3% in the fourth quarter. Bank of Montreal Can now owns 5,879 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,888 shares in the last quarter. Finally, Advisor Group Inc. raised its stake in shares of Array Biopharma by 39.2% in the fourth quarter. Advisor Group Inc. now owns 6,105 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 1,720 shares in the last quarter. Institutional investors own 97.92% of the company’s stock.
Shares of ARRY stock traded up $0.04 during mid-day trading on Friday, hitting $22.39. 2,677,880 shares of the stock were exchanged, compared to its average volume of 2,166,257. The firm has a market cap of $4.89 billion, a price-to-earnings ratio of -30.67 and a beta of 1.48. Array Biopharma Inc has a 12-month low of $12.56 and a 12-month high of $25.05. The company has a debt-to-equity ratio of 0.46, a quick ratio of 6.31 and a current ratio of 6.31.
ARRY has been the topic of several analyst reports. Zacks Investment Research upgraded Array Biopharma from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Wednesday, January 23rd. BidaskClub upgraded Array Biopharma from a “hold” rating to a “buy” rating in a research note on Wednesday, January 9th. Cantor Fitzgerald set a $30.00 price objective on Array Biopharma and gave the company a “buy” rating in a research note on Tuesday, February 5th. Finally, Leerink Swann started coverage on Array Biopharma in a report on Thursday, January 17th. They issued an “outperform” rating and a $28.00 target price on the stock. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Array Biopharma has an average rating of “Buy” and a consensus target price of $26.50.
In related news, CEO Ron Squarer sold 213,438 shares of the firm’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $18.40, for a total transaction of $3,927,259.20. Following the transaction, the chief executive officer now owns 338,709 shares of the company’s stock, valued at $6,232,245.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Carrie Smith Cox acquired 5,000 shares of Array Biopharma stock in a transaction that occurred on Tuesday, February 19th. The stock was purchased at an average price of $23.20 per share, with a total value of $116,000.00. Following the transaction, the director now owns 8,000 shares of the company’s stock, valued at $185,600. The disclosure for this purchase can be found here. In the last three months, insiders have sold 936,069 shares of company stock worth $19,030,369. Corporate insiders own 2.10% of the company’s stock.
Array Biopharma Profile
Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation.
See Also: What is the yield curve?
Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.